No primary source documents a distinct cat-arthritis event in August 2026. The meaningful recent changes are a June Solensia label revision, July safety data, and an April experimental stem-cell update. Cat arthritis, usually osteoarthritis, is joint degeneration that can cause pain and reduced mobility. The new information sharpens treatment expectations and safety monitoring but does not establish a cure.
Table of Contents
- What changed before August 2026?
- How much benefit did Solensia show?
- What do the adverse-event reports mean?
- Is stem-cell treatment close to approval?
- What should cat owners do now?
What changed before August 2026?
The FDA's July 14 release summarized cumulative adverse-event reports for Solensia through June 30. Solensia, or frunevetmab, is a veterinarian-prescribed antibody injected under the skin once monthly to control osteoarthritis pain. The June 2026 FDA label still describes pain control—not cartilage repair or reversal of arthritis.
owners should therefore judge treatment by changes in comfort and everyday movement, not by an expectation that damaged joints will recover. No newly documented august approval, warning, or clinical result appears in the supplied evidence. The date matters because an "August update" should not be mistaken for an August regulatory action.
How much benefit did Solensia show?
In the FDA's 112-day controlled field study, 182 cats received Solensia and 93 received a control. At day 56, owner-reported mobility success was 75.1% with Solensia and 64.8% with the control. That difference supports a pain-control benefit, but it does not show that every cat improves.
The trial also covered roughly three months, so it cannot answer every question about years of treatment. The label says effects beyond six months have not been evaluated. It also says safe use alongside nonsteroidal anti-inflammatory drugs, or NSAIDs, has not been established in cats.
What do the adverse-event reports mean?
The FDA received 7,626 cat Solensia adverse-event reports from January 13, 2022, through June 30, 2026. Frequently reported signs among subcutaneous-use reports included skin scabs, vomiting, lethargy, itching, and lack of efficacy. These reports are signals for monitoring, not proof of causation. The FDA's July 2026 report says voluntary reports cannot establish incidence or compare risk between drugs because exposure totals are unavailable.
Other illnesses and medicines may also contribute. Anaphylaxis, a severe allergic reaction, requires special attention. The label directs veterinarians to discontinue Solensia and treat hypersensitivity if anaphylaxis occurs. UK regulators had previously added anaphylaxis to the product information after pharmacovigilance monitoring. For each injection, owners can record:.
- Jumping, stair use, grooming, play, and ease of entering the litter box
- New scabs, itching, vomiting, unusual tiredness, or apparent loss of benefit
- The injection date and any other medicines or health changes
- Questions for the veterinarian before combining Solensia with an NSAID
Is stem-cell treatment close to approval?
Gallant reported early results for an experimental intravenous therapy made from uterine-derived mesenchymal stromal cells. These cells are being studied for their possible therapeutic effects; the product is not an approved arthritis treatment. In a 35-cat, 90-day pilot, caregivers reported quality-of-life improvement in 76.2% of treated cats and 36.4% of placebo cats.
However, the company's April announcement said the findings had only been submitted for publication. FDA-CVM pathway eligibility is not product approval. Watch for peer-reviewed results, larger controlled studies, longer follow-up, and an actual regulatory decision before treating the therapy as an available option.
What should cat owners do now?
Arthritis can be easy to miss because many changes look like aging or altered behavior. Radiographic joint changes appear in up to 90% of cats, yet only about half are clinically affected. An X-ray finding alone therefore does not show how much pain a cat has. Owners can help by documenting changes in movement and routine, then sharing those observations with a veterinarian.
Current American College of Veterinary Surgeons guidance favors individualized, multimodal care. That may include veterinarian-selected pain relief, weight management, and easier access around the home. Practical changes can include low-entry litter boxes, stable steps to favored resting places, and food or water placed within comfortable reach. Any medication combination, including Solensia with an NSAID, needs veterinary review because its safe use has not been established.